文献速递白血病造血干细胞移植与细胞治疗

靶向CLL-1的CAR-T细胞的研制及功能验证

[Development and functional verification of CAR-T cells targeting CLL-1].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

研究通过流式细胞术检测AML细胞系和原代细胞CLL-1表达,构建CLL-1 CAR载体并制备CAR-T细胞,在体外和AML人源性异种移植小鼠模型中验证功能。制备的CAR-T细胞转导率为77.82%,可特异性杀伤CLL-1阳性靶细胞并分泌IL-6、IFN-γ等细胞因子(P<0.001),在小鼠模型中表现出抗白血病活性并延长存活时间。

要点

  • AML细胞系和原代AML细胞中均表达CLL-1靶点。
  • 制备的CLL-1 CAR-T细胞转导率为77.82%。
  • CLL-1 CAR-T细胞在AML人源性异种移植小鼠模型中表现出抗白血病活性并延长小鼠存活时间。

核心结论

  • 靶向CLL-1的CAR-T细胞成功开发并具有较好的肿瘤杀伤作用。

研究设计与样本

  • 通过流式细胞术检测AML细胞系和AML原代细胞CLL-1靶点表达水平。
  • 构建CLL-1 CAR载体并制备相应慢病毒,感染激活后T细胞生产CAR-T细胞。
  • 通过体外和体内实验验证CLL-1 CAR-T细胞功能,体内实验采用AML人源性异种移植小鼠模型。

主要发现

  • AML细胞系和原代AML细胞中均表达CLL-1。
  • 制备的CLL-1 CAR-T细胞转导率为77.82%。
  • 在AML细胞系及AML原代细胞中,CLL-1 CAR-T细胞能明显特异性杀伤表达CLL-1的靶细胞系和原代肿瘤细胞。
  • 相对于未转导的T细胞,CLL-1 CAR-T细胞杀伤靶细胞和原代肿瘤细胞时分泌IL-6、IFN-γ等细胞因子水平更高(P值均<0.001)。
  • 在AML人源性异种移植小鼠模型中,相对于未转导的T细胞,CLL-1 CAR-T细胞表现出有效的抗白血病活性并延长小鼠存活时间[未达到 vs 22(95%CI 19~24)d,P=0.002]。

关键数值与推荐

  • CLL-1 CAR-T细胞转导率为77.82%。
  • CLL-1 CAR-T细胞较未转导T细胞分泌IL-6、IFN-γ等细胞因子水平更高,P值均<0.001。
  • AML人源性异种移植小鼠模型中,CLL-1 CAR-T细胞组小鼠存活时间未达到 vs 未转导T细胞组22(95%CI 19~24)d,P=0.002。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the development of a CAR-T cells targeting CLL-1 and verify its function. Methods: The expression levels of CLL-1 targets in cell lines and primary cells were detected by flow cytometry. A CLL-1 CAR vector was constructed, and the corresponding lentivirus was prepared. After infection and activation of T cells, CAR-T cells targeting CLL-1 were produced and their function was verified in vitro and in vivo. Results: CLL-1 was expressed in acute myeloid leukemia (AML) cell lines and primary AML cells. The transduction rate of the prepared CAR T cells was 77.82%. In AML cell lines and AML primary cells, CLL-1-targeting CAR-T cells significantly and specifically killed CLL-1-expressing cells. Compared to untransduced T cells, CAR-T cells killed target cells and secreted inflammatory cytokines, such as interleukin-6 and interferon-γ, at significantly higher levels (P<0.001) . In an in vivo human xenograft mouse model of AML, CLL-1 CAR-T cells also exhibited potent antileukemic activity and induced prolonged mouse survival compared with untransduced T cells [not reached vs 22 days (95%CI 19-24 days) , P=0.002]. Conclusion: CAR-T cells targeting CLL-1 have been successfully produced and have excellent functions. 目的: 探索开发一种靶向CLL-1的嵌合抗原受体T细胞(CAR-T细胞)并验证其功能。 方法: 通过流式细胞术检测急性髓系白血病(AML)细胞系和AML原代细胞CLL-1靶点的表达水平。构建CLL-1 CAR载体并制备出相应慢病毒,感染激活后T细胞生产出CAR-T细胞,并通过体外和体内实验验证CLL-1 CAR-T细胞的功能。 结果: AML细胞系和原代AML细胞中均表达CLL-1。制备的CLL-1 CAR-T细胞转导率为77.82%,在AML细胞系以及AML原代细胞中,CLL-1 CAR-T细胞能明显特异性杀伤表达CLL-1的靶细胞系和原代肿瘤细胞。相对于未转导的T细胞,CLL-1 CAR-T细胞在杀伤靶细胞和原代肿瘤细胞时分泌IL-6、IFN-γ等细胞因子水平更高(P值均<0.001)。在AML人源性异种移植小鼠模型中,相对于未转导的T细胞,CLL-1 CAR-T细胞表现出有效的抗白血病活性并延长小鼠存活时间[未达到对22(95%CI 19~24)d,P=0.002]。 结论: 靶向CLL-1的CAR-T细胞成功开发并具有较好的肿瘤杀伤作用。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chai X, Jin X, Zhao MF, et al. [Development and functional verification of CAR-T cells targeting CLL-1]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35381669. doi:10.3760/cma.j.issn.0253-2727.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。